Literature DB >> 10069710

Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G.

M R Passos-Bueno1, M Vainzof, E S Moreira, M Zatz.   

Abstract

The autosomal recessive limb-girdle muscular dystrophies (AR-LGMDs) are a heterogeneous group of disorders of progressive weakness of the pelvic and shoulder girdle musculature. The clinical course is characterized by great variability, ranging from severe forms with onset in the first decade and rapid progression resembling clinically Xp21 Duchenne muscular dystrophy (DMD) to milder forms with later onset and slower course. Eight genes are mapped for the AR-LGMDs; they are: LGMD2A (CAPN3) at 15q, LGMD2B (dysferlin) at 2p, LGMD2C (gamma-SG) at 13q, LGMD2D (alpha-SG) at 17q, LGMD2E (beta-SG) at 4q, LGMD2F (6-SG) at 5q, LGMD2G at 17q, and more recently LGMD2H at 9q. The LGMD2F (delta-SG) and LGMD2G genes were mapped in Brazilian AR-LGMD families. Linkage analysis in two unlinked families excluded the eight AR-LGMD genes, indicating that there is at least one more gene responsible for AR-LGMD. We have analyzed 140 patients (from 40 families) affected with one of seven autosomal recessive LGMD loci, that is, from LGMD2A to LGMD2G. The main observations were: 1) all LGMD2E and LGMD2F patients had a severe condition, but considerable inter- and intra-familial clinical variability was observed among patients from all other groups; 2) serum CK activities showed the highest values in LGMD2D (alpha-SG) patients among sarcoglycanopathies and LGMD2B (dysferlin) patients among nonsarcoglycanopathies; 3) comparison between LGMD2A (CAPN3) and LGMD2B (dysferlin) showed that the first have on average a more severe course and have calf hypertrophy more frequently (86% versus 13%); and 4) inability to walk on toes was observed in approximately 70% of LGMD2B patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069710     DOI: 10.1002/(sici)1096-8628(19990219)82:5<392::aid-ajmg7>3.0.co;2-0

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  A new evidence for the maintenance of the sarcoglycan complex in muscle sarcolemma in spite of the primary absence of delta-SG protein.

Authors:  Telma L F Gouveia; Patrícia M Kossugue; Julia F Paim; Mayana Zatz; Louise V B Anderson; Vincenzo Nigro; Mariz Vainzof
Journal:  J Mol Med (Berl)       Date:  2007-01-30       Impact factor: 4.599

2.  Diagnostic yield of multi-gene panel for muscular dystrophies and other hereditary myopathies.

Authors:  Pablo Brea Winckler; Bruna Cristine Chwal; Marco Antonnio Rocha Dos Santos; Daniela Burguêz; Marcia Polese-Bonatto; Edmar Zanoteli; Marina Siebert; Filippo Pinto E Vairo; Márcia Lorena Fagundes Chaves; Jonas Alex Morales Saute
Journal:  Neurol Sci       Date:  2022-02-17       Impact factor: 3.307

3.  Findings of limb-girdle muscular dystrophy R7 telethonin-related patients from a Chinese neuromuscular center.

Authors:  Kun Huang; Qiu-Xiang Li; Hui-Qian Duan; Yue-Bei Luo; Fang-Fang Bi; Huan Yang
Journal:  Neurogenetics       Date:  2022-01-04       Impact factor: 2.660

4.  Clinical and pathological characteristics of four Korean patients with limb-girdle muscular dystrophy type 2B.

Authors:  Seung-Hun Oh; Seong-Woong Kang; Jin-Goo Lee; Sang-Jun Na; Tai-Seung Kim; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

Review 5.  [Limb girdle muscular dystrophies].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

6.  Muscle phenotypic variability in limb girdle muscular dystrophy 2 G.

Authors:  Julia F Paim; Ana Cotta; Antonio P Vargas; Monica M Navarro; Jaquelin Valicek; Elmano Carvalho; Antonio L da-Cunha; Estevão Plentz; Shelida V Braz; Reinaldo I Takata; Camila F Almeida; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2013-03-12       Impact factor: 3.444

Review 7.  Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies.

Authors:  Volker Straub; Kate Bushby
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

8.  Dysferlin protein analysis in limb-girdle muscular dystrophies.

Authors:  M Vainzof; L V Anderson; E M McNally; D B Davis; G Faulkner; G Valle; E S Moreira; R C Pavanello; M R Passos-Bueno; M Zatz
Journal:  J Mol Neurosci       Date:  2001-08       Impact factor: 2.866

9.  Phenotypic and immunohistochemical characterization of sarcoglycanopathies.

Authors:  Ana F B Ferreira; Mary S Carvalho; Maria Bernadete D Resende; Alda Wakamatsu; Umbertina Conti Reed; Suely Kazue Nagahashi Marie
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  How to tackle the diagnosis of limb-girdle muscular dystrophy 2A.

Authors:  Marina Fanin; Anna Chiara Nascimbeni; Elisabetta Tasca; Corrado Angelini
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.